Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Characterization of UDP-glucuronosyltransferase 2A1 (UGT2A1) variants and their potential role in tobacco carcinogenesis.

Bushey RT, Chen G, Blevins-Primeau AS, Krzeminski J, Amin S, Lazarus P.

Pharmacogenet Genomics. 2011 Feb;21(2):55-65. doi: 10.1097/FPC.0b013e328341db05.

2.

Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen.

Lazarus P, Blevins-Primeau AS, Zheng Y, Sun D.

Ann N Y Acad Sci. 2009 Feb;1155:99-111. doi: 10.1111/j.1749-6632.2009.04114.x. Review.

3.

Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites.

Blevins-Primeau AS, Sun D, Chen G, Sharma AK, Gallagher CJ, Amin S, Lazarus P.

Cancer Res. 2009 Mar 1;69(5):1892-900. doi: 10.1158/0008-5472.CAN-08-3708. Epub 2009 Feb 24.

4.

Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp>Tyr) polymorphism.

Chen G, Blevins-Primeau AS, Dellinger RW, Muscat JE, Lazarus P.

Cancer Res. 2007 Oct 1;67(19):9024-9.

5.

Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases.

Sun D, Sharma AK, Dellinger RW, Blevins-Primeau AS, Balliet RM, Chen G, Boyiri T, Amin S, Lazarus P.

Drug Metab Dispos. 2007 Nov;35(11):2006-14. Epub 2007 Jul 30.

PMID:
17664247
6.

Glucuronidation of PhIP and N-OH-PhIP by UDP-glucuronosyltransferase 1A10.

Dellinger RW, Chen G, Blevins-Primeau AS, Krzeminski J, Amin S, Lazarus P.

Carcinogenesis. 2007 Nov;28(11):2412-8. Epub 2007 Jul 17.

PMID:
17638922

Supplemental Content

Loading ...
Support Center